IN-2401

IN-2401 is a small molecule therapeutic candidate developed by Indivumed, primarily targeting colorectal cancer (CRC). The drug was identified using Indivumed's proprietary multi-omics database and analytics platform, which integrates deep molecular profiling of patient-derived biospecimens with clinical data to uncover novel oncology targets. As of late 2025, IN-2401 is in the IND-enabling stage of preclinical development. While its specific molecular target remains undisclosed, the program represents Indivumed's lead small molecule asset in its CRC-focused pipeline, which aims to address unmet needs in solid tumors through precision medicine.